Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Cardiol Therapeutics Inc. (CRDL)

1.1500
+0.0700
+(6.48%)
At close: April 29 at 4:00:00 PM EDT
1.1500
0.00
(0.00%)
After hours: April 29 at 4:05:05 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CRDL

Recent News: CRDL

View More
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Newsfile 12 hours ago
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Newsfile 13 days ago
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Simply Wall St. 27 days ago
Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Newsfile 28 days ago
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Newsfile last month
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Newsfile 2 months ago
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Newsfile 2 months ago
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
GlobeNewswire 4 months ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Newsfile 5 months ago
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
GlobeNewswire 5 months ago
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Newsfile 6 months ago
View More

Related Tickers

JUSHF Jushi Holdings Inc.
0.3296
+9.87%
 
TSNDF TerrAscend Corp.
0.3680
+15.00%
 
KNSA Kiniksa Pharmaceuticals International, plc
25.88
+20.54%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.2930
-0.07%
 
AVCNF Avicanna Inc.
0.1700
-2.30%
 
LOVFF Cannara Biotech Inc.
1.0500
+3.96%
 
SSLCF SIMPLY SOLVENTLESS CONCENTRATES
0.4500
0.00%
 
PCLO.V PharmaCielo Ltd.
0.0700
0.00%
 
IMCC IM Cannabis Corp.
1.5000
+0.67%
 
AAWH Ascend Wellness Holdings, Inc.
0.3900
+2.63%